Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma
File(s)African Paper NMJ_final.docx (110.84 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Hepatocellular carcinoma (HCC) exhibits a huge disease burden on West Africa, with a large proportion of all HCC cases worldwide occurring in the sub-region. The high HCC prevalence is due to the endemicity of a number of risk factors, most notably hepatitis B, C and HIV. West African HCC also displays a poor prognosis. Generally speaking, this is owing to more aggressive tumours, late patient presentation and inadequate management. Exposure to chronic viral hepatitis, more carcinogenic West African strains of hepatitis B virus and carcinogens such as aflatoxin B1 all encourage tumour growth. Lack of patient confidence in the healthcare system contributes to poor health-seeking behaviors and management of the disease can be lacking, due in part to poor health infrastructure, resources available and lack of access to expensive treatment. There is also much we do not know about West African HCC, especially the effect rising obesity and alcohol use may have on this disease in the future. Suggestions for improvement are discussed, including surveillance of high-risk groups. Although there is much to be done before West African HCC is thought to be a curable disease, many steps have been taken to move in the right direction.
Date Issued
2015-11-17
Date Acceptance
2015-11-01
Citation
Nigerian Medical Journal, 2015, 56 (4), pp.231-235
ISSN
2229-774X
Publisher
Medknow Publications
Start Page
231
End Page
235
Journal / Book Title
Nigerian Medical Journal
Volume
56
Issue
4
Copyright Statement
© 2015 Nigerian Medical Journal. This article is distributed under the Creative Commons Attribution-Noncommercial-Share Alike 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/)
Sponsor
Association of Physicians of Great Britain & Ireland
British Liver Trust
Trustees of the London Clinic
European Association for the Study of Liver
Identifier
http://www.ncbi.nlm.nih.gov/pubmed/26759504
PII: NMJ-56-231
Grant Number
N/A
N/A
N/A
N/A
Subjects
Aflatoxin
Hepatitis B
Hepatitis C
Hepatocellular carcinoma
Liver cancer
Medical And Health Sciences
Publication Status
Published
Coverage Spatial
Nigeria